莫西沙星联用头孢哌酮钠舒巴坦钠治疗老年重症肺炎的临床效果分析  

Analysis of the clinical effect of moxifloxacin combined with cefoperazone sodium and sulbactam sodium in the treatment of senile severe pneumonia

作　　者：曲思澄 QU Si-cheng(Heping Hospital,General Hospital of the Northern Theater Command,Shenyang 110000,China)

机构地区：[1]北部战区总医院和平院区干三科,110000

出　　处：《中国实用医药》2022年第16期136-138,共3页China Practical Medicine

摘　　要：目的分析对老年重症肺炎(SP)患者应用莫西沙星联合头孢哌酮钠舒巴坦钠治疗的临床价值。方法78例老年重症肺炎患者,根据随机数字表法分为观察组和对照组,每组39例。对照组应用头孢哌酮钠舒巴坦钠治疗,观察组则采用莫西沙星联合头孢哌酮钠舒巴坦钠治疗。比较两组患者临床疗效、临床症状(退热、肺部炎症吸收、咳痰)消失时间、血清炎症指标[白细胞计数(WBC)和C反应蛋白(CRP)]、不良反应发生情况。结果观察组治疗总有效率97.44%高于对照组的84.62%,差异具有统计学意义(P<0.05)。观察组患者退热时间(2.13±0.52)d、肺部炎症吸收时间(5.75±1.59)d以及咳痰消失时间(5.69±1.63)d均短于对照组的(3.16±1.05)、(7.62±1.97)、(7.85±1.69)d,差异均具有统计学意义(P<0.05)。治疗后,观察组WBC(6.13±0.65)×109/L、CRP(3.62±0.35)mg/L低于对照组的(8.06±0.79)×109/L、(11.19±1.15)mg/L,差异均具有统计学意义(P<0.05)。两组治疗中均未见不良反应。结论对于老年重症肺炎患者采用莫西沙星联合头孢哌酮钠舒巴坦钠治疗可取得确切疗效,有利于加快患者病情康复并降低炎症反应。Objective To analyze the clinical value of moxifloxacin combined with cefoperazone sodium and sulbactam sodium in the treatment of senile severe pneumonia(SP).Methods A total of 78 senile patients with severe pneumonia were divided into observation group and control group according to the random numerical table,with 39 cases in each group.The control group was treated with cefoperazone sodium and sulbactam sodium,while the observation group was treated with moxifloxacin combined with cefoperazone sodium and sulbactam sodium.Both groups were compared in terms of clinical efficacy,clinical symptoms(fever reduction,pulmonary inflammation absorption,expectoration)disappearance time,serum inflammatory indicators[white blood cell count(WBC)and C-reactive protein(CRP)],and occurrence of adverse reactions.Results The total effective rate 97.44%of the observation group was higher than 84.62%of the control group,and the difference was statistically significant(P<0.05).The antipyretic time(2.13±0.52)d,the absorption time of pulmonary inflammation(5.75±1.59)d and the disappearance time of expectoration(5.69±1.63)d in the observation group were all shorter than(3.16±1.05),(7.62±1.97),and(7.85±1.69)d in the control group,and the differences were statistically significant(P<0.05).After treatment,the WBC(6.13±0.65)×109/L and CRP(3.62±0.35)mg/L in the observation group were lower than(8.06±0.79)×109/L and(11.19±1.15)mg/L in the control group,and the differences were statistically significant(P<0.05).No adverse reactions occurred in the two groups.Conclusion For senile patients with severe pneumonia,combined use of moxifloxacin and cefoperazone sodium and sulbactam sodium can achieve definite curative effect,which is beneficial to accelerate the recovery of patients and reduce inflammatory response.

关 键 词：老年重症肺炎 莫西沙星 头孢哌酮钠舒巴坦钠 价值 

分 类 号：R563.1[医药卫生—呼吸系统]